Abstract
Purpose of review: As the incidence of cutaneous melanoma continues to rise worldwide, its heterogeneous presentation proves challenging for managing and preventing relapse.
Recent findings: While surgery remains a mainstay in staging and treatment of locoregional metastatic melanoma, intralesional therapies have emerged as a new tool to treat unresectable in-transit and nodal metastases and reduce the risk of relapse through immunomodulatory mechanisms. In this review, we will provide an overview of intralesional therapies for melanoma with a particular focus on talimogene laherparepvec (T-VEC) and its future uses. We then discuss the landscape of current and emerging intralesional therapies.
Publication Date
12-1-2024
Content Type
Article
PubMed ID:
Citation
Kalsi, S., Galenkamp, A. L., Singh, R., Khosla, A. A., McGranaghan, P., & Cintolo-Gonzalez, J. (2024). Talimogene laherparepvec (T-VEC) and Emerging Intralesional Immunotherapies for Metastatic Melanoma: A Review. Current oncology reports, 26(12), 1651–1663. https://doi.org/10.1007/s11912-024-01611-9
Comments
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. © 2024